177Lu-DOTATATE在儿童及年轻成人人群中的安全性与疗效:单中心经验
这项单中心回顾性研究纳入19例≤29岁晚期不可手术/转移性神经内分泌肿瘤患者,接受中位4周期177Lu-DOTATATE联合低剂量卡培他滨放疗增敏,客观缓解率41%、疾病控制率94%,仅见1–2级不良事件,中位随访80.1个月,估计5年无进展生存54%、总生存63%;作者认为该方案在该人群看似安全有效,需大型前瞻性试验验证。
要点
- 19例≤29岁晚期神经内分泌肿瘤患者接受177Lu-DOTATATE,客观缓解率41%、疾病控制率94%。
- 不良事件均为1级(14例,74%)或2级(5例,26%),未见更高级别毒性报告。
- 中位随访80.1个月,估计5年无进展生存54%(95%CI 30–78)、总生存63%(95%CI 39–87)。
核心结论
- 作者认为177Lu-DOTATATE在转移性/不可手术神经内分泌肿瘤的儿童及年轻成人中看似安全有效,需大型前瞻性试验验证这些结果。
研究设计与样本
- 单中心回顾性研究,纳入所有≤29岁、经活检证实的晚期不可手术/转移性上皮或非上皮性神经内分泌肿瘤的儿童及年轻成人患者。
主要发现
- 共19例患者,中位年龄22±10岁,其中8例为青少年(10–18岁)、其余为年轻成人(19–29岁)。
- 14例为胃肠胰神经内分泌肿瘤(胰腺为最常见原发部位),其余为非胃肠胰神经内分泌肿瘤。
- 共给予65个周期177Lu-DOTATATE(范围1–6周期),中位累积活度600 mCi(范围100–1000 mCi)。
- 客观缓解率为41%,疾病控制率为94%。
- 1级和2级不良事件分别见于19例中的14例(74%)和5例(26%)。
关键数值与推荐
- 患者接受中位4周期177Lu-DOTATATE治疗,每8–12周给药,并口服低剂量卡培他滨作为放疗增敏剂,例外为2例接受CAPTEM化疗。
- 疗效采用RECIST 1.1标准在 interim 及治疗结束时68Ga-DOTANOC PET/CT上评估。
- 主要终点为客观缓解率,次要终点为疾病控制率、毒性特征、无进展生存和总生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为单中心回顾性研究。
- 作者指出需大型前瞻性试验验证这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This single-center retrospective study explores the safety and efficacy of 177 Lu-DOTATATE in children and young adult population with metastatic/inoperable neuroendocrine tumors (NETs). PATIENTS AND METHODS: This study is a retrospective analysis of all children and young adult patients (≤29 years) with advanced inoperable/metastatic epithelial or nonepithelial NETs who were administered a median of 4 cycles of 177 Lu-DOTATATE therapy and low-dose oral capecitabine as a radiosensitizer every 8-12 weeks, except 2 patients who received CAPTEM chemotherapy. The radiological response was assessed using RECIST 1.1 on interim and end-of-treatment 68 Ga-DOTANOC PET/CT. The primary endpoint was objective response rate, whereas disease control rate, toxicity profile, progression-free survival, and overall survival were secondary endpoints. RESULTS: Nineteen biopsy-proven NET patients (median age, 22 ± 10 years) with 8 of them adolescents (10-18 years) and the remaining young adults (19-29 years) were included. Fourteen patients had gastroenteropancreatic neuroendocrine tumor (pancreas being most common primary site), whereas the rest had non-gastroenteropancreatic neuroendocrine tumor. A total of 65 cycles of 177 Lu-DOTATATE (range, 1-6 cycles) were administered with a median cumulative activity of 600 mCi (range, 100-1000 mCi). The objective response rate and disease control rate were 41% and 94%, respectively. Grade 1 and 2 adverse events were observed in 14 (74%) and 5 (26%) of 19 patients, respectively. In a total of 8 events (42%), 4 events each of disease progression and death occurred during a median follow-up of 80.1 months with an estimated 5-year progression-free survival and overall survival of 54% (95% confidence interval, 30-78) and 63% (95% confidence interval, 39-87), respectively. CONCLUSIONS: 177 Lu-DOTATATE appears safe and effective in children and young adults with metastatic/inoperable NETs. Large prospective trials are required to validate these results.
引用
- Aggarwal P, Satapathy S, Sood A, et al. Safety and Efficacy of 177 Lu-DOTATATE in Children and Young Adult Population : A Single-Center Experience. Clin Nucl Med. 2024. PMID: 38769655. doi:10.1097/RLU.0000000000005233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。